Not really. The second french clinical test independent from Raoult has shown that most patients don't react to plaquenil+azythromycin and a
chinese clinical trial goes in the same direction. Also the argument doesn't actually work when Sanofi, the ones owning plaquenil, increased the production of plaquenil, if anything we should look at the links between Raoult and Sanofi.
Angers CHU started a new clinical trial that is supposed to be less amateurish and much larger with 1300 patients. Below you have a researcher from the CNRS explaining where the problem lies with Raoult and his experiment, basically he botched everything.